docAnniversary and Retirement symposium Professor
download 
Report Transcription
Anniversary and Retirement symposium Professor Herman Autrup, PhD, Fellow ATS Friday 25 September 2015 Location: Samfundsmedicinsk Auditorium. Bldg 1262, Bartholins Allé 2 10.00 -10.10 Welcome v. Søren Kjærgaard, Institute of Public Health 10.10-10.50 Professor Herman Autrup Living in harmony with chemicals 10.50-11.05 Coffee 11.05-11.35 Professor Haakan Wallin, National Research Center for the Working Environment Copenhagen Safety of nanoparticles 11.35-12.05 Professor Ole Raaschou-Nielsen, Danish Cancer Society, Copenhagen Air Pollution and cancer 12.05-12. 50 Professor Soterios Kyrtopolus, Institute of Biology, Medicinal Chemistry and Biotechnology, National Hellenic Research Foundation, Athens Greece From Aulis to Omics – The evolving drama of biomarkers in Environmental Health 12.50-13.30 Lunch Break 13.30 -14.15 Professor Roland Wolf, University of Dundee, UK Application of humanized models to study the metabolism and side effects of anticancer drugs 14.15-15.00 Curtis Harris, National institute of Cancer, Bethesda USA Cancer Epidemiology and Biomarkers: A precision Medicine Strategy 15.00- Reception
Similar documents
How to get to Dansk Standard (Danish Standards Association) Kollegievej 6 DK-2920 Charlottenlund
EPO Biomarkers Market Growth, Trends, Absolute Opportunity and Value Chain 2016-2026
Erythropoietin is special type of protein biomarker, also known as a growth factor. It acts by the stimulating the bone marrow to manufacture red blood cells. There are five different types of erythropoietin biomarkers such as epoetin alfa, epoetin beta, epoetin zeta, epoetin theta and darbepoetin alfa. Erythropoietin is mostly administered subcutaneously as an alternative to iron supplements. Erythropoietin used in human beings is also known as recombinant human erythropoietin (rHuEPO). Commercially available rHuEPO has the same 165 amino acid sequence as available in naturally occurring hormone but the level of glycosylation in rHuEPO depends on the testing method used. Growing global incidence of renal diseases and cancers is expected to create a marked increase in use of EPO biomarkers.
